Literature DB >> 3087305

Mode of cerebral vasodilating action of KC-404 in isolated canine basilar artery.

M Ohashi, J Kito, K Nishino.   

Abstract

3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) caused a potent and concentration-dependent relaxation in isolated canine basilar artery precontracted with prostaglandin (PG) F2 alpha attended by EC50 of 7.6 X 10(-8) g/ml. The relaxing action of KC-404 was little affected by the removal of vascular endothelium, whereas it was significantly diminished by pretreatment with indomethacin (10(-5) M) or acetylsalicylic acid (ASA) (10(-3) M). In PGF2 alpha-contracted canine basilar artery, KC-404-induced relaxation was markedly reversed to contraction by the subsequent addition of indomethacin (10(-5) M), ASA (10(-3) M) and phenidone (10(-4) M) by about 80%, 75% and 111%, respectively, whereas it was little affected by nordihydroguaiaretic acid (NDGA) (10(-5) M). Similar results were obtained when dipyridamole was used as a relaxant but, in contrast, papaverine-induced relaxation was little affected by indomethacin. KC-404 as well as PGI2 showed less potent or no relaxation in both PGF2 alpha-contracted rabbit aorta and KCl-contracted canine basilar artery as compared with PGF2 alpha-contracted canine basilar artery. In PGF2 alpha-contracted canine basilar artery, PGI2-induced relaxation was significantly augmented by pretreatment with KC-404 (10(-8) and 10(-7) g/ml). These results suggest that KC-404 might elicit cerebral vasorelaxation not dependent on vascular endothelium but remarkably dependent on a vasodilating cyclooxygenase metabolite, possibly PGI2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087305

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  1 in total

1.  Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model.

Authors:  K Takuma; E Lee; R Enomoto; K Mori; A Baba; T Matsuda
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.